Continuous Glucose Monitoring Devices Market To Reach $41.41 Billion By 2033

Continuous Glucose Monitoring Devices Market Growth & Trends

The global continuous glucose monitoring devices market size is expected to reach USD 41.41 billion by 2033, registering a CAGR of 15.10% from 2026 to 2033, according to a new report by Grand View Research, Inc. Growing cases of diabetes and introduction of novel and advanced diabetes care and management devices are the major factors driving the market growth. Continuous glucose monitoring (CGM) devices provide an efficient method to measure body glucose levels in real time. Data recorded by these devices is transmitted through a wireless network to receivers; this helps keep track of glucose levels over a designated period.

With the advent of digital therapeutics, a rising number of continuous glucose monitoring devices are being incorporated with apps and software to help patients with diabetes mellitus. Apps such as Glucose buddy, Diabetes Connect, MySugar, and others are available under paid subscription. Further, the rise in the number of diabetes mellitus has contributed significantly toward the global market growth. The device allows real time biofeedback and behavioral change support, allowing effective management of diabetes by the patient. Additionally, the government is spending a huge amount on diabetic care tools to closely monitor diabetes in patient. For instance, according to American Diabetes Association, the overall cost of diagnosed diabetes in the United States for the year 2022 is estimated to be USD 412.9 billion. This amount encompasses direct medical costs of USD 306.6 billion and indirect costs of USD 106.3 billion associated with diabetes.

Diabetes management demands intensive efforts to maintain normal glucose levels and reduce complications, decrease healthcare expenditures, & prevent premature death. This involves monitoring blood sugar levels, taking insulin, following a proper diet, and regular exercising. However, the current sensor technology used to monitor glucose levels only works with a “one-size-fits-all” approach, which does not cater to the special needs of subpopulations such as senior citizens, ethnic minorities, children, adolescents, and people with limited resources. To rectify this, future diabetes technology must be adaptable to diverse users. The ideal devices should be customizable, user-friendly, and affordable. These devices can also be combined with behavioral interventions to promote patient- & family-centered care and provide decision-support tools for clinicians. Although there have been significant advancements in CGM technology, its widespread use is still limited by biological, pharmacological, and socioeconomic factors. Aforementioned factors suggests continuous glucose monitoring devices market growth in the near future.

 Request a free sample copy or view report summary: Continuous Glucose Monitoring Devices Market Report

Continuous Glucose Monitoring Device Market Report Highlights

• The sensors segment accounted for the largest market share of 62.8% in 2025 and is projected to grow at a CAGR of 15.34% over the forecast period. Sensors form the core component of CGM systems, as they continuously measure glucose levels in interstitial fluid and transmit data to receivers or connected mobile applications.

• The Bluetooth segment accounted for the largest market share of 57.3% in 2025 and it is projected to grow at a CAGR of 13.12% over the forecast period. CGM sensors are equipped with Bluetooth chips.

• The Type 1 diabetes segment dominated the market in 2025, with a share of 64.9% and is anticipated to grow at a CAGR of 14.83% over the forecast period. People suffering from Type 1 diabetes (T1D) are the primary users of CGM devices, owing to their lifelong requirement for insulin and the critical need to tightly regulate glucose levels.

• The pharmacies segment is expected to have the largest market share 59.4% of the market in 2025, and it is projected to grow at a CAGR of 15.16% over the forecast period, which is driven by their accessibility, trusted role in chronic disease management, and evolving business models that now support prescription and over-the-counter (OTC) CGM product sales.

• The North American continuous glucose monitoring devices market with the largest revenue share of 63.3% in 2025, driven by the increasing prevalence of diabetes, rising adoption of CGM devices, technological advancements, and the presence of key companies.

Continuous Glucose Monitoring Devices Market Segmentation

Grand View Research has segmented the global continuous glucose monitoring devices market on the basis of product, connectivity, indication, distribution channel, and region:

Continuous Glucose Monitoring Devices Product Outlook (Revenue, USD Million, 2021 - 2033)

• Sensors

• Device/Readers

• Applicators

• Transmitters

Continuous Glucose Monitoring Devices Connectivity Outlook (Revenue, USD Million, 2021 - 2033)

• Bluetooth

• 4G/Cellular

• Near Field Communication (NFC)

Continuous Glucose Monitoring Devices Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Type 1 Diabetes

• Type 2 Diabetes

Continuous Glucose Monitoring Devices Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Pharmacies

• E-commerce

• Other

Continuous Glucose Monitoring Devices Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Continuous Glucose Monitoring Devices Market

• DexCom, Inc.

• Abbott Laboratories

• Medtronic plc

• Sensonics, Inc.

• Sinocare, Inc. (iCan CGM)

• i-SENS, Inc.

• Zhejiang POCTech Co., Ltd.

• GlucoRx Limited (AiDEX, Vixxa)

• F. Hoffmann-La Roche Ltd.

• Nemaura

• Bionime (RIGHTEST iFree CGM)